PRIMARY STUDY
Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review
Key Findings: This review suggests that targeting different mechanisms of the endocannabinoid system has potential therapeutic effects in the treatment of inflammatory bowel disease (IBD). The mechanism of reducing inflammation is summarized in this review.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Australia, Poland
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2, GPCR 55, PPAR - Alpha, PPARs
Ligands Studied: Pro-inflammatory cytokines
Citation: Hryhorowicz S, et al. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review. Front Immunol. 2021; 12:790803. doi: 10.3389/fimmu.2021.790803
Authors: Hryhorowicz S, Kaczmarek-Ryś M, Zielińska A, Scott RJ, Słomski R, Pławski A
